# Next Steps Roadmap - Multi-Omics Integration Project

**Current Status**: ✅ Comprehensive multi-omics integration pipeline completed successfully

---

## 🎯 Immediate Next Steps (Priority 1)

### 1. Model Validation & Refinement

#### 1.1 External Validation
- [ ] **E-GEOD-15629** (ArrayExpress) - 19 samples for external validation
  - Status: Requires manual download
  - Action: Download and validate models on independent dataset
  - Expected: Validate tissue model (AUC 0.930) and blood model (AUC 0.612)

#### 1.2 Model Optimization
- [ ] **Hyperparameter Tuning**
  - Current: Using default sklearn parameters
  - Action: Grid search / Bayesian optimization for:
    - Random Forest: n_estimators, max_depth, min_samples_split
    - SVM: C, gamma, kernel
    - Gradient Boosting: learning_rate, n_estimators, max_depth
  - Expected: Potential AUC improvement of 0.01-0.05

- [ ] **Feature Selection Refinement**
  - Current: Top 100 DE genes
  - Action: 
    - Recursive feature elimination (RFE)
    - LASSO regularization for feature selection
    - Correlation-based feature selection
  - Expected: Reduce features while maintaining/increasing performance

- [ ] **Class Imbalance Handling**
  - Current: class_weight='balanced'
  - Action: Try SMOTE, ADASYN, or other oversampling techniques
  - Expected: May improve blood model performance

#### 1.3 Cross-Dataset Validation
- [ ] **Leave-One-Study-Out Validation**
  - Validate tissue model on external tissue datasets
  - Validate blood model on external blood datasets
  - Measure performance degradation

---

## 🔬 Biological Interpretation & Analysis (Priority 2)

### 2.1 Pathway-Level Integration

- [ ] **Identify Common Pathways**
  - Action: Load and compare pathway enrichment results
  - Current: Tissue has 4 pathways, Blood has 1 pathway
  - Goal: Find common biological processes between tissue and blood
  
- [ ] **Pathway Network Analysis**
  - Action: Build interaction networks for enriched pathways
  - Tools: Cytoscape, STRING database
  - Goal: Understand pathway crosstalk

- [ ] **Functional Annotation**
  - Action: Deep dive into top pathway terms:
    - ECM remodeling (collagen-containing extracellular matrix)
    - Basement membrane
    - External encapsulating structure
  - Goal: Understand biological mechanisms

### 2.2 Gene-Level Integration

- [ ] **True Gene ID Conversion**
  - Current: Limited conversion (only 4 DE genes in tissue)
  - Action: 
    - Expand to all significant genes (not just DE)
    - Use biomaRt or mygene.info for comprehensive mapping
    - Map to common gene symbols for integration
  - Goal: Find common signature genes across datasets

- [ ] **Shared Biomarker Discovery**
  - Action: Identify genes that are:
    - Significant in both tissue and blood
    - Show consistent directionality
    - Have literature support
  - Goal: Develop multi-modal biomarker panel

### 2.3 Literature Integration

- [ ] **Validate Against Known Biomarkers**
  - Action: Compare signature genes with literature:
    - Known aneurysm markers (ELN, COL1A1, COL3A1, etc.)
    - GWAS-validated loci
    - Previous transcriptomics studies
  - Goal: Confirm biological relevance

---

## 📊 Advanced Analysis (Priority 3)

### 3.1 Ensemble Model Refinement

- [ ] **Weighted Ensemble**
  - Current: Separate models for each dataset
  - Action: 
    - Combine tissue + blood predictions with weights
    - Optimize weights based on performance
    - Use stacked generalization
  - Goal: Better performance than individual models

- [ ] **Multi-Modal Integration**
  - If paired samples become available:
    - Build true multi-omics model (tissue + blood for same patients)
    - Use early/late fusion approaches
    - Implement attention mechanisms for feature selection

### 3.2 Risk Stratification

- [ ] **Develop Risk Scores**
  - Action:
    - Create continuous risk scores from model predictions
    - Define risk categories (low/medium/high)
    - Validate risk stratification
  - Goal: Clinical utility

- [ ] **Nomogram Development**
  - Action: Combine:
    - Transcriptomics risk score
    - Clinical variables (age, hypertension, etc.)
    - Imaging features (size, location, etc.)
  - Goal: Clinical decision support tool

### 3.3 Subtype Analysis

- [ ] **Identify Patient Subtypes**
  - Action:
    - Clustering based on gene expression
    - Identify molecular subtypes
    - Correlate with clinical outcomes
  - Goal: Precision medicine approach

---

## 🏥 Clinical Translation (Priority 4)

### 4.1 Biomarker Panel Development

- [ ] **qPCR Validation Panel**
  - Action:
    - Select top 20-50 genes from signature
    - Design qPCR assays
    - Validate in independent cohort
  - Current resources:
    - `results/qpcr_panel_top20.tsv` (if available)
    - `results/blood_top_20_genes.tsv`
    - `results/tissue_top_20_genes.tsv`
  - Goal: Clinically feasible biomarker panel

- [ ] **Multi-Modal Panel**
  - Action: Combine:
    - Blood transcriptomics markers
    - Tissue signature genes
    - GWAS risk loci (PRS)
  - Goal: Comprehensive risk assessment

### 4.2 Clinical Validation Studies

- [ ] **Prospective Validation**
  - Action: Design and conduct prospective validation study
  - Requirements:
    - Independent patient cohort
    - Follow-up for clinical outcomes
    - Standardized sample collection
  - Goal: Clinical implementation

- [ ] **Meta-Analysis**
  - Action: Combine results with:
    - Other published studies
    - External validation datasets
    - Meta-analyze performance
  - Goal: Robust evidence base

---

## 📝 Publication & Documentation (Priority 5)

### 5.1 Manuscript Preparation

- [ ] **Methods Section**
  - Document:
    - Data preprocessing pipeline
    - Model training procedures
    - Validation strategies
    - Integration approaches

- [ ] **Results Section**
  - Present:
    - Model performance metrics
    - Signature gene lists
    - Pathway enrichment results
    - Ensemble predictions

- [ ] **Figures & Tables**
  - Create:
    - ROC curves for all models
    - Feature importance plots
    - Pathway network diagrams
    - Heatmaps of signature genes
    - Prediction calibration plots

### 5.2 Supplementary Materials

- [ ] **Gene Lists**
  - Export comprehensive signature gene lists
  - Include annotations (gene symbols, functions)
  - Provide expression values

- [ ] **Code Repository**
  - Organize and document:
    - Analysis scripts
    - Model files (if saved)
    - Data processing pipelines
  - Goal: Reproducibility

---

## 🔄 Data Acquisition (Priority 6)

### 6.1 Additional Datasets

- [ ] **dbGaP Access**
  - Action: Apply for access to intracranial aneurysm studies
  - Goal: Genotype data for PRS calculation
  - Benefit: Patient-level PRS integration

- [ ] **Author Contacts**
  - [ ] Dr. Ynte Ruigrok (GSE122897) - Request paired blood samples or genotype data
  - [ ] Dr. Poppenberg (GSE159610) - Request paired tissue samples or genotype data
  - Goal: True multi-omics integration (same patients)

- [ ] **Additional GEO Datasets**
  - Search for:
    - Additional tissue RNA-seq datasets
    - Additional blood RNA-seq datasets
    - Single-cell RNA-seq for cell-type specificity
  - Goal: Larger sample sizes for validation

### 6.2 Genotype Data Integration

- [ ] **PRS Calculation**
  - If genotype data becomes available:
    - Calculate patient-level PRS
    - Integrate with transcriptomics signatures
    - Build combined risk model
  - Current resources:
    - `results/prs_weights.tsv`
    - `results/prs_risk_loci_top17.tsv`

---

## 🛠️ Technical Improvements

### 7.1 Pipeline Optimization

- [ ] **Automation**
  - Create automated pipeline for:
    - New data ingestion
    - Model retraining
    - Result generation
  - Goal: Scalability

- [ ] **Version Control**
  - Implement proper versioning for:
    - Data versions
    - Model versions
    - Analysis scripts
  - Goal: Reproducibility

- [ ] **Quality Control**
  - Implement:
    - Data quality checks
    - Model performance monitoring
    - Anomaly detection
  - Goal: Reliability

### 7.2 Advanced Modeling

- [ ] **Deep Learning**
  - Explore:
    - Neural networks for non-linear relationships
    - Autoencoders for feature learning
    - Attention mechanisms for interpretability
  - Goal: Potentially better performance

- [ ] **Bayesian Methods**
  - Implement:
    - Bayesian logistic regression
    - Bayesian model averaging
    - Uncertainty quantification
  - Goal: Better uncertainty estimates

---

## 📋 Action Plan Summary

### This Week
1. ✅ Complete comprehensive integration pipeline (DONE)
2. [ ] Review and validate all results
3. [ ] Create visualization figures
4. [ ] Document findings

### This Month
1. [ ] External validation on E-GEOD-15629 (if available)
2. [ ] Hyperparameter tuning for models
3. [ ] Pathway integration analysis
4. [ ] Biomarker panel selection

### Next 3 Months
1. [ ] Prospective validation study design
2. [ ] Apply for dbGaP access
3. [ ] Contact authors for paired samples
4. [ ] Manuscript preparation

### Long-term (6-12 months)
1. [ ] Clinical validation studies
2. [ ] qPCR panel development
3. [ ] Publication submission
4. [ ] Clinical implementation planning

---

## 🎯 Success Metrics

### Model Performance
- [ ] Maintain/improve tissue model AUC > 0.90
- [ ] Improve blood model AUC > 0.70
- [ ] External validation AUC > 0.85 (tissue)

### Biomarker Development
- [ ] Identify 20-50 validated biomarker genes
- [ ] Develop qPCR panel
- [ ] Validate in independent cohort

### Clinical Translation
- [ ] Prospective validation study designed
- [ ] Risk stratification tool developed
- [ ] Clinical decision support tool created

---

## 📚 Resources Available

### Data
- ✅ GSE122897 (Tissue) - 43 samples
- ✅ GSE159610 (Blood) - 47 samples
- ⚠️ E-GEOD-15629 (Validation) - 19 samples (manual download needed)

### Results Files
- ✅ `results/comprehensive_multi_omics_model_summary.tsv`
- ✅ `results/ensemble_tissue_predictions.tsv`
- ✅ `results/ensemble_blood_predictions.tsv`
- ✅ `results/pathway_enrichment_prioritized_fdr_0.05.tsv`
- ✅ `results/gse122897_differential_expression.tsv`
- ✅ `results/gse159610_full_de_results.tsv`

### Analysis Scripts
- ✅ `execute_comprehensive_integration.py` - Main pipeline
- ✅ `comprehensive_multi_omics_integration.py` - Advanced version
- ✅ Previous analysis scripts available

---

## ⚠️ Challenges & Considerations

### Current Limitations
1. **Different Patients**: Tissue and blood datasets have different patients
   - Solution: Build separate models (current approach) or wait for paired samples

2. **Blood Model Performance**: Lower AUC (0.612)
   - Potential solutions:
     - Larger sample size
     - Feature engineering
     - Class balancing
     - External validation

3. **Limited Gene ID Conversion**: Only 4 DE genes in tissue at FDR < 0.05
   - Solution: Use less stringent thresholds or all expressed genes

4. **Sample Size**: Relatively small datasets
   - Solution: Combine with external datasets, apply for additional data

### Recommendations
1. **Prioritize External Validation**: Most important next step
2. **Focus on Tissue Model**: Already excellent performance (AUC 0.930)
3. **Improve Blood Model**: Needs optimization
4. **Pathway Integration**: High biological value
5. **Biomarker Panel**: High clinical value

---

## 🚀 Quick Wins (Can Do Today)

1. **Create Visualization Plots**
   - ROC curves for all models
   - Feature importance plots
   - Pathway enrichment plots

2. **Gene List Export**
   - Export comprehensive signature gene lists
   - Add annotations

3. **Pathway Comparison**
   - Compare tissue and blood pathways
   - Identify common biological processes

4. **Risk Score Development**
   - Create continuous risk scores
   - Define risk categories

---

**Last Updated**: November 17, 2025  
**Status**: Ready for next phase of analysis

